PCV148 Impact Laws And Decrees On Activities: The Ilda Study  by Citarella, A. et al.
A498  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  
ing to attitudes and beliefs relevant to the therapy area. Results: Quantitative 
segmentation identified key distinct segments of payers displaying unique atti-
tudes and beliefs towards entry of the novel class of anticoagulation agents. The 
segmentation approach identified key differentiating factors between segments, 
allowing full profiling of each group. Payers’ underlying values were explored 
with a view to gain insight to what is important to them as individuals as well as 
decision makers, what motivates them and what restricts them. ConClusions: 
Findings from this research were utilized to prioritise targeting of payer segments. 
In addition, communication and messaging strategies were optimised for these 
payer groups. Subsequently a post-project feedback workshop with the pharma-
ceutical client was conducted. The poster will discuss how the research was used 
by the pharmaceutical client and the benefits of this strategic tool to the brand 
team.
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objeCtives: To assess whether the prescribing pattern of statins changed after 
reimbursement criteria revision and regional policies in a general practice in 
southern Italy. Methods: Analysis has been performed on a database of 123 
medical practitioners that have managed an average of 190.000 inhabitants in 
the Campania Region (south of Italy). Prevalence of use and incidence of new 
treatments were calculated from Jan 2012 to Jun 2013. Statin users were stratified 
into three groups (Moderate Cardiovascular Risk, MR; High Cardiovascular Risk, 
HR; Very High Cardiovascular Risk, VHR) according to new criteria for reimburse-
ment for lipid lowering agents revised by the Italian Drug Agency (AIFA) (Nota 13).  
Results: After the reimbursement criteria revision (November 2012), the prev-
alence of statin use slightly decreased reaching 6.6% in the second quarter of 
2013 (-14% compared to second quarter of 2012). Stratified by level of CV risk, the 
prevalence of statin use is reduced by 24.9% into MR, 13.1% into HR and 5.9% into 
VHR, while incidence of new users of 22.4%, 34 5% and 45.8% respectively. In the 
second quarter of 2013, atorvastatin (+45.3%) was prescribed in 57,5% of patients 
in MR group (+45.3%), rosuvastatin 5.9% with (-60.1%) and 1.6% with simvasta-
tin + ezetimide (-57.5%); in HR group, 40.7% (+20.8) atorvastatin, 5.3% (-57.0%) 
rosuvastatin and 2.1% (- 42.3%) simvastatin + ezetimide; in VHR, 56.3% (+15.8) 
atorvastatin, 12.5% (-37.5%) rosuvastatin and 2.1% (-27.1%) simvastatin + ezetim-
ide. ConClusions: The revision of reimbursement criteria and the regional poli-
cies led to significant changes in general practice in southern Italy resulting in a 
reduction in the statin use, especially in patients who could potentially benefit 
from it most. The results of the study provide useful information for the general 
practitioner about areas for improvement prescriptive.
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objeCtives: Frequent legislative changes that have brought the Slovak health care 
reform over the past decade, reflected also on drug policy and especially on the 
prices of medicines and total consumption of medicines. Generic substitution was 
introduced to save both health insurance and patient’s finances. Methods: Data 
on prices and consumption of lipid-lowering agent medicines were collected from 
Slovak Ministry of Health and Health insurance. Data processing, we used a uniform 
methodology recommended by the WHO - ATC / DDD classification and basic statisti-
cal methods of observing. In case of national data, we reported consumption in units 
of DDD per 1,000 inhabitants for one day (DID). Results: A class of lipid-lowering 
agent medicines (C10A) poses in recent years on Slovak market expanding group. Its 
number significantly increased in direct proportion with the introduction of generic 
drugs, mainly after 2004, when generic substitution was enacted and later after 
2011, when mandatory generic prescribing entry into the force. The proportion of 
total medicines and generic drugs in the group C10A were x2008total-medicines/%generic-
drugs= 55/74,6 types and x2014total-medicines/%generic-drugs= 203/94 types. The number of 
generic drugs with atorvastatin ranged x2008-2014= 4-18, rosuvastatin x2008-2014= 3-11, 
simvastatin x2008-2014= 7-7, fluvastatin x2008-2014= 1-1, lovastatin x2008-2014= 1-5. The 
consumption of medicines with atorvastatin x2008-2014-packages= +Δ 47,7%, x2008-2014-
value= +Δ 20,1% € , rosuvastatin x2008-2014-packages= +Δ 18,8%, x2008-2014-value= -Δ 77,4 % € , 
simvastatin x2008-2014-packages= -Δ 48,6%, x2008-2014-value= -Δ 79,6 % € , fluvastatin x2008-
2014-packages= -Δ 50,5%, x2008-2014-value= -Δ 90,4 % € , lovastatin x2008-2014-packages= -Δ 70,1%, 
x2008-2014-value= -Δ 81,8 % € . In the years 2008-2013 consumption of C10A in Slovakia 
increased by 77,5 per DDD/1000 inh. /day (DID). OECD statistics from 2011 indicate 
consumption of lipid-lowering agents amounting to 130 DID, while at the end of 
2013 according to our data analysis increased to 142.8 DID. ConClusions: Overall 
changes in legislation of drug policy brought rising utilization of lipid-lowering agent 
medicines and in 2011 Slovakia together with Great Britain was on the second place 
with 130 DID consumption of lipid-lowering agents.
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following with 15% of the rest patients switching to rivaroxaban per year. Then the 
model estimates the number of DVT, pulmonary embolism (PE), intracranial bleeds 
(ICH) and major extracranial bleeds (ECH) per year. Results: The new DVT patients 
are 287,813 per year. For those patients, with 20% patients switching to rivaroxa-
ban from LMWH+VKA in the first year, the recurrent venous thrombus embolism 
(VTE) events, including DVT and PE, reduced 4.6%, major bleeding events including 
ECH and ICH reduced 7% with 1% minor bleeding increasing. To the third year, the 
recurrent VTE events reduced 11.4%, major bleeding events reduced 17% with 2% 
minor bleeding increasing compared with the current situation. ConClusions: 
Rivaroxaban may decrease the clinical burden of DVT in China by reducing the 
incidence of recurrent VTE and fatal bleeding events. Decision-makers can find the 
exact value of rivaroxaban easily by the simple tool in different situations.
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objeCtives: Disease management programs (DMPs) for cardiovascular risk (CVR) 
and chronic obstructive pulmonary disease (COPD) are increasingly implemented 
in the Netherlands to improve quality of care and patient’s lifestyle. The aim of 
the study was to provide evidence about the (cost-) effectiveness of Dutch DMPs 
as implemented in daily practice. Methods: We compared the 2-year costs 
and changes in physical activity, smoking behaviour, and utilities between the 
most and the least comprehensive DMP in four disease categories: primary CVR-
prevention, secondary CVR-prevention, both types of CVR-prevention, and COPD 
(total n: 1034). Propensity score matching increased comparability between DMPs. 
A cost-utility analysis was performed from the health care and societal perspective. 
Sensitivity analysis was performed to estimate the impact of DMP development and 
implementation costs on the cost-effectiveness. Results: Patients in the most 
comprehensive DMPs increased physical activity and had higher smoking cessation 
probabilities after 2 years in most disease categories. From a health care perspec-
tive, the incremental costs were positive in primary CVR-prevention (96% certainty), 
negative in secondary and both types of CVR prevention (93% and 98% certainty) and 
indifferent in COPD. The incremental QALYs were positive in all categories (certainty 
range: 64%-80%). The incremental cost-effectiveness ratio’s ranged from € -114,662 
to € 8,849. The results from the societal perspective and the sensitivity analysis were 
in the same line. ConClusions: The most comprehensive DMPs for CVR and COPD 
were cost-effective compared to the least comprehensive DMPs. The challenge for 
Dutch stakeholders is to find the optimal mixture of interventions.
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objeCtives: This study examines the extent to which Integrated Care Programs 
lead to an improvement in the quality of patient care. The aim of the study is 
to carry out a quantitative analysis of differences in quality between patients 
participating in Disease Management Programs (DMPs) and patients receiving 
regular care, regardless of health insurance status, program, or region. Methods: 
The study used data from the representative IMS Disease Analyzer database. It 
included patients with a confirmed diagnosis of hypertension who started anti-
hypertensive therapy in the period between January 2010 and December 2012. 
The primary dependent variable of the study was the change in blood pressure 
after at least six months of antihypertensive treatment. To assess this variable, we 
determined the proportion of patients with a blood pressure of below 140/90 in the 
period between day 183 and day 365 after initiation of treatment (index date). In 
order to eliminate confounding factors, we performed one-to-one matching based 
on a propensity score. Results: 1,317 patients participating in the integrated 
care program (ICP) and 1,317 patients not participating in such a program were 
available for further analyses following the propensity score matching. Patients 
in both groups were very similar with respect to demographic variables and 
antihypertensive therapy. The proportion of patients with blood pressure values 
< 140/90 after one year of treatment was 33.6% in the group of ICP participants 
and 22.7% in the group of non-ICP patients (p< 0.0001). The chance of reaching 
the treatment goal was significantly higher in the group of patients participating 
in an integrated health program (OR: 1.73; 95% CI: 1.45-2.05). ConClusions: It 
is evident that DMP participants have a significantly better chance of achieving 
the therapy goal. Thus, it can be established that integrated health care programs 
have a positive effect on quality.
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objeCtives: The research aimed to develop an attitudinal based, payer segmen-
tation approach to explore payers’ attitudes and behaviours towards the man-
aged entry of novel agents in the anticoagulation area in the health care systems 
of countries within the EU. The segmentation exercise explored payers’ drivers, 
motivations, barriers and limitations when assessing, endorsing or restricting new 
agents. Methods: Qualitative in-depth telephone interviews were conducted 
to explore payers’ views, along with perceived challenges relating to the entry of 
novel class of anticoagulation agents. Followed by a quantitative data collection 
and advanced statistical analysis methodology was employed with regional and 
local payers in each of the researched markets to define the segmentation accord-
